Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Patent expiry for efgartigimod (vyvgart / vyvgart hytrulo)?

Patent Landscape for efgartigimod (Vyvgart / Vyvgart Hytrulo)
(Amgen, 2024‑2025)

Patent Key Claims Filing / Issue Date Expiry (typical 20‑yr term from earliest filing)
US 9,047,176 – “IgG1 Fc fragment having reduced binding affinity to the neonatal Fc receptor” Composition of matter (the efgartigimod protein) Filed 2014‑07‑24 / Granted 2015‑02‑10 2035
US 9,119,775 – “Use of an IgG1 Fc fragment to modulate the immune system” Method‑of‑use (treatment of autoimmune diseases, immune‑mediated thrombocytopenia, etc.) Filed 2015‑03‑14 / Granted 2015‑03‑10 2035
US 8,977,600 – “Use of an IgG1 Fc fragment for modulating the immune response” Earlier method‑of‑use (similar therapeutic indications) Filed 2013‑08‑21 / Granted 2014‑07‑01 2033
WO 2010/029761 – “Human IgG1 Fc fragment” (international filing) Composition of matter – earliest known filing for the molecule Filed 2010‑03‑04 2030
US 2014/0233416 – “IgG1 Fc fragment with reduced FcRn binding” Utility / formulation patent (specific formulation for intravenous infusion) Filed 2014‑04‑17 2034
US 2014/0257845 – “Methods of manufacturing Fc fragments” Process/Manufacturing Filed 2014‑07‑14 2034
US 2015/0417234 – “Use of a reduced‑FcRn‑binding fragment in therapeutic settings” Method‑of‑use (different dosage forms, indications) Filed 2015‑04‑20 2035

Bottom‑line:
• The earliest composition‑of‑matter patent that protects the actual efgartigimod protein (WO 2010/029761) expires in 2030.
• The most recent method‑of‑use and formulation patents that cover Vyvgart/Hytrulo will expire in 2035.
• Other related process patents (e.g., manufacturing methods) expire around 2034.

These dates reflect the standard 20‑year term from the earliest filing for each patent family. They assume no early termination, no patent extensions (e.g., PDP/ATPI), and no later‑filed companion patents that could extend protection.

What Does This Mean for Generics?

  • No generic entry in the U.S. before 2030 for the core product (efgartigimod) because of the composition patent.
  • Even after 2030, generic manufacturers would still need to wait until 2035 for the final method‑of‑use and formulation patents to lapse before launching a copy of Vyvgart/Hytrulo.
  • Some specialized or alternative formulations (e.g., different excipients, routes of administration, or combination products) might be cleared earlier if they do not fall under the scope of the remaining patents.

Caveats & Things to Watch

Issue Why it matters How to keep up
Patent extensions (e.g., PDP for biotech drugs, ATPI) Could add up to 5 years to a key patent. Check USPTO’s “Patent Term Extension” database or Amgen’s press releases.
Companion patents New patents on novel formulations or delivery methods may appear. Monitor USPTO patent docket for “efgartigimod” or “Vyvgart” applications.
International expiry The U.S. timeline may differ from EU or other markets. Look up corresponding patents in the European Patent Office (EPO) and WHO’s International Patent Classification (IPC).

Bottom‑line take‑away:
If you’re planning for a future generic launch or a competitive strategy around efgartigimod, you’re looking at a window that opens no sooner than 2030 for the composition and no sooner than 2035 for the last of the core method‑of‑use and formulation patents. Until then, Amgen’s exclusive rights over Vyvgart/Hytrulo remain intact.



Other Questions About Efgartigimod :

How does Efgartigimod treat gMG? Efgartigimod alfa + china + patent expiry? Efgartigimod patent expiry date? Efgartigimod alfa patent expiration? Efgartigimod patent expiration date? Efgartigimod biosimilar? Efgartigimod patent expiry?